Apogee Therapeutics Inc. (NASDAQ:APGE) is highlighted as one of the best healthcare stocks with the highest upside potential. BTIG analyst Julian Harrison maintains a Buy rating with a price target of $115 based on the company’s promising clinical developments, particularly the potential of APG777 in treating various conditions. The expected best-in-class features of APG777 and narrowing timelines for clinical data support the Buy rating. Apogee Therapeutics Inc. offers treatments for COPD, AD, and I&I indications, with ongoing data updates and trials reinforcing the company’s positive outlook.

Read more at Yahoo Finance: BTIG Maintains a Buy on Apogee Therapeutics (APGE)